SAB4504246
抗 磷酸-IRAK1 (pThr 209 ) 兔抗
affinity isolated antibody
别名:
Anti-IRAK, Anti-pelle
登录 查看组织和合同定价。
选择尺寸
关于此项目
NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
ELISA
western blot
western blot
Species reactivity:
human
Citations:
10
Technique(s):
ELISA: 1:40000
western blot: 1:500-1:1000
western blot: 1:500-1:1000
Uniprot accession no.:
产品名称
抗 磷酸-IRAK1 (pThr 209 ) 兔抗, affinity isolated antibody
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
76 kDa
species reactivity
human
concentration
~1 mg/mL
technique(s)
ELISA: 1:40000
western blot: 1:500-1:1000
NCBI accession no.
UniProt accession no.
application(s)
research pathology
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
phosphorylation (pThr209)
Quality Level
Gene Information
human ... IRAK1(3654)
Application
兔中产生的抗磷酸化-IRAK1（pThr209）抗体已用于免疫沉淀沉淀。
Biochem/physiol Actions
白介素1受体相关激酶1（IRAK1）是白介素1受体（IL-1R）信号通路的重要组成部分。IRAK1作为toll样受体（TLR）信号通路的下游效应分子起作用，与炎症、自身免疫和癌症有关。IRAK1与系统性红斑狼疮（SLE）相关，在包括肺癌在内的多种癌症类型中均过表达。IRAK1，被认为是骨髓增生异常综合征（MDS）、急性髓性白血病（AML）、三阴性乳腺癌（TNBC）转移和紫杉醇耐药中的潜在治疗靶标。IRAK1表达增加会导致头颈部鳞状细胞癌（HNSCC）。因此，抑制IRAK1可能是HNSCC的新治疗策略。
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
Features and Benefits
完放心地使用我们的抗体。如果抗体在您的申请的研究中不起作用，我们将全额退款或安排替代抗体。了解更多信息。
General description
白介素1受体相关激酶1（IRAK1）是一种丝氨酸/苏氨酸激酶，由具有14个外显子的基因编码，定位于人染色体xq28。编码的蛋白质属于IRAK家族。IRAK1的特征是在其N末端具有死亡结构域，该结构域参与蛋白质相互作用。
Immunogen
针对Thr209磷酸化位点周围人IRAK1衍生的合成肽产生抗血清。
免疫原范围： 175-224
免疫原范围： 175-224
Physical form
兔IgG，溶于磷酸盐缓冲液（不含Mg2+和Ca2+），pH 7.4,150mM NaCl，0.02％叠氮化钠和50％甘油中。
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
此项目有
IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.
Allie K Adams et al.
Oncotarget, 6(41), 43395-43407 (2015-11-04)
The chromatin-binding DEK protein was recently reported to promote the growth of HPV+ and HPV- head and neck squamous cell carcinomas (HNSCCs). Relevant cellular and molecular mechanism(s) controlled by DEK in HNSCC remain poorly understood. While DEK is known to
Xiuling Zhang et al.
International journal of clinical and experimental pathology, 7(11), 8096-8104 (2015-01-01)
The interleukin-1 receptor associated kinases 1 (IRAK1) is a down stream effector molecule of the toll like receptor (TLR) signaling pathway, which is involved in inflammation, autoimmunity and cancer. However, the role of IRAK1 in lung cancer remains unclarified. Herein
Yosuke Tanaka et al.
Nature communications, 13(1), 271-271 (2022-01-14)
Leukemia stem cells (LSCs) in chronic myeloid leukemia (CML) are quiescent, insensitive to BCR-ABL1 tyrosine kinase inhibitors (TKIs) and responsible for CML relapse. Therefore, eradicating quiescent CML LSCs is a major goal in CML therapy. Here, using a G0 marker
Devram S Ghorpade et al.
Nature, 555(7698), 673-677 (2018-03-22)
Obesity-induced metabolic disease involves functional integration among several organs via circulating factors, but little is known about crosstalk between liver and visceral adipose tissue (VAT). In obesity, VAT becomes populated with inflammatory adipose tissue macrophages (ATMs). In obese humans, there
Baohuan Cai et al.
Molecular cancer, 20(1), 165-165 (2021-12-16)
Stem Cell leukemia/lymphoma syndrome (SCLL) presents as a myeloproliferative disease which can progress to acute myeloid leukemia and is associated with the coincident development of B-cell and T-cell lymphomas. SCLL is driven by the constitutive activation of fibroblast growth factor
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持